Dowling & Yahnke’s Regulus Therapeutics RGLS Stock Holding History

Dowling & Yahnke’s Portfolio RGLS Stock Details RGLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,200	Closed	-$4K	–	385
2022 Q1	$4K	Hold	1,200	–	–	﹤0.01%	375
2021 Q4	$4K	Hold	1,200	–	–	﹤0.01%	377
2021 Q3	$8K	Hold	1,200	–	–	﹤0.01%	372
2021 Q2	$10K	Hold	1,200	–	–	﹤0.01%	367
2021 Q1	$19K	Hold	1,200	–	–	﹤0.01%	337
2020 Q4	$16K	Hold	1,200	–	–	﹤0.01%	327
2020 Q3	$6K	Hold	1,200	–	–	﹤0.01%	307
2020 Q2	$8K	Buy	+1,200	New	+$7.85K	﹤0.01%	300
2018 Q4	–	Sell	-100	Closed	-$2K	–	274
2018 Q3	$2K	Hold	100	–	–	﹤0.01%	282
2018 Q2	$8K	Hold	100	–	–	﹤0.01%	275
2018 Q1	$9K	Buy	100 +4	+4%	+$535	﹤0.01%	280
2017 Q4	$12K	Hold	96	–	–	﹤0.01%	291
2017 Q3	$14K	Hold	96	–	–	﹤0.01%	277
2017 Q2	$11K	Hold	96	–	–	﹤0.01%	276
2017 Q1	$19K	Buy	+96	New	+$18.3K	﹤0.01%	276

Other funds holding RGLS

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Dowling & Yahnke's RGLS Position: Q2 2022 in Review

Dowling & Yahnke sold out of Regulus Therapeutics (RGLS) in Q2 2022, closing a stake of 1,200 shares — an estimated $4K sold.

Dowling & Yahnke first reported a position in RGLS in Q1 2017 and held it in 15 quarters. The position peaked at $19K in Q1 2021. 27 funds tracked by Wall St. Rank hold RGLS as of Q2 2022.

Dowling & Yahnke reported no remaining Regulus Therapeutics position as of Q2 2022 after selling out during the quarter.
Dowling & Yahnke sold 1,200 Regulus Therapeutics shares in Q2 2022, an estimated $4K.
Dowling & Yahnke first reported a position in Regulus Therapeutics in Q1 2017 and held it in 15 quarters.
Dowling & Yahnke's Regulus Therapeutics position peaked at $19K in Q1 2021.
27 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2022.

Based on Dowling & Yahnke's 13F filing for Q2 2022, filed 10 Aug 2022.